<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
AGRX
Agile Therapeutics
$
()


  • Agile Therapeutics reports Q4 EPS ($1.51) vs (10c) last year

    3/28/2024 - 08:07am
  • Agile Therapeutics announces delisting from Nasdaq

    3/25/2024 - 16:35pm
  • Agile Therapeutics cut to Hold at Maxim on revenue miss, likely cash needs

    3/18/2024 - 08:10am
  • Maxim gets more bearish on Agile Therapeutics, downgrades shares

    3/18/2024 - 07:54am
  • Agile Therapeutics completes payoff of debt

    3/13/2024 - 07:37am
  • Agile Therapeutics announces exercise of warrants for $4.8M gross proceeds

    2/22/2024 - 09:13am
  • Agile Therapeutics granted extension by Nasdaq to regain compliance

    2/15/2024 - 16:50pm
  • Agile Therapeutics notes Biden administration guidance on contraceptive access

    1/23/2024 - 09:30am
  • Agile provides update on actions to strength ACA's no-cost contraceptive rule

    12/12/2023 - 08:27am
  • Agile Therapeutics files to sell $15M of common stock, Series E-1 warrants

    12/11/2023 - 17:32pm
  • Agile Therapeutics reports Q3 EPS ($1.47) vs ($3.10) last year

    11/9/2023 - 08:18am
  • Wayfair upgraded, Deere downgraded: Wall Street's top analyst calls

    9/22/2023 - 09:38am
  • Agile Therapeutics upgraded to Buy from Hold at Maxim

    9/22/2023 - 08:01am
  • Agile Therapeutics sees 2023 net revenue $25M-$30M

    8/9/2023 - 08:10am
  • Agile Therapeutics reports Q2 adjusted EPS ($3.10) vs. ($135.46) last year

    8/9/2023 - 08:09am
dynamic_feed Breaking News